Advinus Therapeutics, a TATA group, contract research services and pharmaceutical drug discovery company, based in Bangalore announced that it has started its US operations by incorporating a wholly owned subsidiary, Advinus Therapeutics Inc.
The U.S. Company will be operating out of its office in Research Triangle Park, North Carolina.
Advertisement
In addition the company also announced that it has appointed Dr. Eric Nelson as its Global Head of Business Development, Marketing and Strategy.
Dr. Nelson with over 20 years of corporate and business development experience with both large pharmaceutical and biotechnology companies would be based out of the company's US office and will have the responsibility of managing its operations.
Eric joins Advinus from Tranzyme Pharma where he was Vice President of Business Development and Licensing. Previously he was Assistant Vice President of Global Business Development at Wyeth Pharmaceuticals.
Speaking on the start of US operations, Dr. Rashmi Barbhaiya, the CEO and Managing Director of the company stated, Advinus has a very large and growing client base in the US. In addition we now have multiple drug discovery alliances and collaborations with both Large Pharma and Biotechs based out of the US. One of the main reasons to start the US operations of our company is to build on these relationships and to expand into new ones.
Rajiv Malik, the SVP and Head of Business Operations at Advinus added, Having Eric as our Head of Business Development in the US would help bridge the distance that most US companies feel when working with R and D companies in this part of the world. Now a US based company does not have to wait till the end of business day for them to be able to talk to us.
Source: ANI
SPH
Advertisement
Eric joins Advinus from Tranzyme Pharma where he was Vice President of Business Development and Licensing. Previously he was Assistant Vice President of Global Business Development at Wyeth Pharmaceuticals.
Speaking on the start of US operations, Dr. Rashmi Barbhaiya, the CEO and Managing Director of the company stated, Advinus has a very large and growing client base in the US. In addition we now have multiple drug discovery alliances and collaborations with both Large Pharma and Biotechs based out of the US. One of the main reasons to start the US operations of our company is to build on these relationships and to expand into new ones.
Rajiv Malik, the SVP and Head of Business Operations at Advinus added, Having Eric as our Head of Business Development in the US would help bridge the distance that most US companies feel when working with R and D companies in this part of the world. Now a US based company does not have to wait till the end of business day for them to be able to talk to us.
Source: ANI
SPH
Advertisement
Advertisement
|
Advertisement
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
